10x Genomics (TXG) News

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive

BenzingaSep 2 00:25

10x Genomics Needs "Meaningful' Growth in Single-Cell Business, RBC Says

10x Genomics (TXG) is offering a compelling product cycle but its two franchises are pulling in opposite directions, RBC Capital Markets said in a note Tuesday."Spatial and single cell represent two

MT NewswiresSep 1 23:22

RBC Capital Maintains 10x Genomics(TXG.US) With Hold Rating, Raises Target Price to $70

RBC Capital analyst Dan Leonard maintains $10x Genomics(TXG.US)$ with a hold rating, and adjusts the target price from $20 to $70.According to TipRanks data, the analyst has a success rate of 61.5%

Futu NewsSep 1 17:32

Express News | 10X Genomics, Inc. : RBC Initiates Coverage With Sector Perform Rating; Target Price $70

BreakingsSep 1 12:28

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.4%.The iShares Biotechnology

MT NewswiresAug 29 04:06

Qiagen Hit With $4.8M Jury Award in Patent Dispute With 10x Genomics

Seeking AlphaAug 29 03:32

Express News | 10X Genomics - to Seek Enhanced Damages and Permanent Injunction Against Parse in U.S.

BreakingsAug 29 02:40

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity

BenzingaAug 26 01:35

SpaceX Continues to Be Cathie Wood's Biggest Weekly Bet; Trims RBLX, PLTR, and AMD

Seeking AlphaAug 24 19:07

Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were mixed, with the Dow Jones index gaining over 200 points on Wednesday.Shares of Estee Lauder Companies Inc (NYSE:EL) rose sharply after the company reported better-than-expected

BenzingaAug 19 22:08

10x Genomics Insider Sold Shares Worth $432,279, According to a Recent SEC Filing

Sarah A. Teichmann, Director, on August 13, 2026, sold 7,551 shares in 10x Genomics (TXG) for $432,279. Following the Form 4 filing with the SEC, Teichmann has control over a total of 28,058 Class A

MT NewswiresAug 18 04:13

Cathie Wood's Ark Adds $30M Cloudflare, $27M Nvidia; Cuts $60M Deere

Seeking AlphaAug 17 18:15

Insider Shake-Up at 10x Genomics Signals a Major Move

TipRanksAug 14 10:10

10x Genomics Insider Sold Shares Worth $1,155,055, According to a Recent SEC Filing

John R Stuelpnagel, Director, on August 11, 2026, sold 20,000 shares in 10x Genomics (TXG) for $1,155,055. Following the Form 4 filing with the SEC, Stuelpnagel has control over a total of 348,436

MT NewswiresAug 14 04:21

Stephens & Co. Maintains Overweight on 10x Genomics, Raises Price Target to $65

Stephens & Co. analyst Mason Carrico maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $50 to $65.

BenzingaAug 13 00:21

J.P. Morgan Remains a Hold on 10x Genomics (TXG)

TipRanksAug 11 20:16

Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $47

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $42 to $47.

BenzingaAug 11 02:37

Insiders Of 10x Genomics Retain US$2.8m Of Investment Selling At Higher Prices

While 10x Genomics, Inc. (NASDAQ:TXG) shareholders have enjoyed a good week with stock up 11%, they need remain vigilant. Even though stock prices were relatively low, insiders elected to sell US$2.8

Simply Wall StAug 10 22:42

Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $60

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $50 to $60.

BenzingaAug 10 20:01

CCORF Maintains 10x Genomics(TXG.US) With Buy Rating, Raises Target Price to $60

CCORF analyst Kyle Mikson CFA maintains $10x Genomics(TXG.US)$ with a buy rating, and adjusts the target price from $50 to $60.According to TipRanks data, the analyst has a success rate of 44.3% and

Futu NewsAug 10 19:34